7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2013-12-31 2013-09-30 2012-12-31 2012-09-30 2011-12-31 2011-09-30 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-12-31 2007-09-30 2007-06-30 2007-03-31 
      
    		                                                 
      cash flows from operating activities:
    		                                                 
      net income
    		-30,744,000 240,532,000 185,686,000 124,943,000 106,080,000 107,174,000 88,662,000 20,375,000 40,378,000 56,040,000 50,852,000 -249,000 -6,652,000 27,664,000 120,798,000 -57,898,000 -36,494,000 12,941,000 17,371,000 22,099,000 784,803,000 -29,183,000 81,381,000 15,024,000 55,036,000 -37,435,000 -56,473,000 -61,990,000 -53,020,000 -53,012,000 -5,357,000 -26,735,000 -17,653,000 -12,189,000 217,334,000 -477,000 1,151,000 4,711,000 6,641,000 1,312,000 -13,152,000 24,506,000 829,000 3,810,000 1,686,000 2,570,000 -5,216,000 -3,864,000 -9,293,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                 
      depreciation and amortization
    		18,487,000 18,563,000 22,069,000 23,607,000 19,006,000 26,463,000 27,350,000 26,861,000 25,685,000 25,419,000 26,421,000 24,553,000 24,802,000 25,271,000 27,343,000 25,986,000 26,839,000 27,231,000 27,983,000 27,358,000 26,634,000 25,216,000 25,964,000 25,790,000 30,739,000 26,344,000 22,427,000 9,384,000 13,375,000 11,857,000 11,667,000 9,628,000 9,350,000 7,931,000 7,819,000 6,577,000 5,410,000 4,861,000 4,841,000 6,170,000 5,103,000 4,757,000 4,554,000 4,450,000 3,870,000 3,705,000 3,489,000 3,313,000 3,036,000 
      non-cash interest expense
    		649,000 660,000 660,000 660,000 718,000 991,000 990,000 990,000 1,140,000 1,029,000 1,029,000 1,028,000 1,027,000 1,029,000 1,033,000 1,032,000 1,032,000 1,039,000 1,043,000 1,745,000 5,232,000 4,916,000 4,618,000 4,565,000 525,000 4,461,000 4,409,000                       
      accretion of discount on investments
    		-978,000 -1,355,000 -1,362,000  -1,941,000 -2,176,000 -2,502,000                   -619,000 -891,000 1,631,000 1,320,000                     
      stock-based compensation
    		49,265,000 47,531,000 37,700,000 51,919,000 43,489,000 47,914,000 58,249,000 54,855,000 48,387,000 50,162,000 53,695,000 46,734,000 54,663,000 47,078,000 47,833,000  49,026,000 54,843,000 49,503,000  50,169,000 44,962,000 46,994,000  39,173,000 39,829,000 42,761,000 23,543,000 16,790,000 11,926,000 11,990,000 11,188,000 11,784,000 9,835,000 10,294,000 9,627,000 8,606,000 9,356,000 9,155,000 8,960,000 8,534,000 8,228,000 8,243,000 6,655,000 5,210,000 5,544,000    
      gain on sale of nonfinancial assets
    		   0 0 0 -10,000,000     0 0 0 -108,000,000     0 0 0 -59,495,000                           
      impairment of assets and other noncash adjustments
    		                                                 
      acquired in-process research & development expense
    		                                                 
      deferred income taxes
    		-13,646,000 33,342,000 28,429,000 42,387,000 12,172,000 1,252,000 285,000 -24,844,000 -15,029,000 1,252,000 -6,360,000 -51,344,000 -4,198,000 -1,345,000 4,800,000 -3,588,000 -13,224,000 -2,131,000 3,335,000 -34,708,000 -848,335,000 -16,467,000 10,603,000 -22,980,000 -49,697,000 -9,379,000 -704,000 10,056,000 -9,490,000 689,000 -10,753,000 -2,481,000 -149,000 -7,512,000                
      unrealized foreign exchange gain
    		5,550,000 4,720,000 -10,026,000 5,599,000 -2,394,000 -9,154,000 -10,804,000 22,992,000 -2,001,000 840,000 6,615,000 1,788,000 -3,742,000                                     
      other
    		212,000 -649,000 -1,267,000 21,389,000 -396,000 -985,000 127,000 -141,000 -585,000 583,000 -222,000 -1,343,000 -682,000 -718,000 700,000 -1,312,000 -941,000 495,000 -871,000 -1,385,000 1,038,000 -267,000 -383,000 -1,661,000 3,585,000 -3,584,000 -19,000               -164,000        
      changes in operating assets and liabilities:
    		                                                 
      accounts receivable
    		48,746,000 -98,534,000 -57,590,000 72,547,000 -74,375,000 -52,695,000 -3,386,000 -58,495,000 13,891,000 -7,035,000 -138,796,000 -28,281,000 38,810,000 -37,749,000 -54,813,000 61,000 48,093,000 -22,874,000 40,294,000 -26,120,000 -24,887,000 23,870,000 -31,898,000 23,951,000 -30,773,000 20,660,000 -51,690,000 6,923,000 -9,682,000 8,224,000 -16,540,000 2,025,000 -451,000 -7,842,000 -1,052,000 4,924,000 -9,066,000 -5,162,000 4,198,000 -11,221,000 -7,057,000 -3,163,000 1,021,000 -4,903,000 -30,277,000 -1,008,000 -67,000 -1,376,000 145,000 
      inventory
    		-26,334,000 -48,127,000 -24,335,000 -34,271,000 18,150,000 -30,589,000 -16,820,000 -59,110,000 -41,472,000 -42,378,000 -14,098,000 -40,845,000 -25,988,000 -2,556,000 1,125,000 -15,935,000 -25,504,000 12,804,000 -6,425,000 12,159,000 -27,012,000 -25,592,000 -20,706,000 -54,983,000 -19,452,000 -34,854,000 1,735,000 -13,921,000 -6,388,000 -7,870,000 -700,000 -14,490,000 -3,329,000 -17,957,000 -7,963,000 -4,017,000 -1,099,000 -3,221,000 -2,605,000 3,586,000 -3,260,000 -5,069,000 -6,293,000 -7,050,000 4,474,000 -895,000 -837,000 -3,276,000 -2,363,000 
      other current assets
    		-17,033,000 -8,765,000 -6,327,000 16,161,000 -21,554,000 18,968,000 -17,353,000 9,054,000 -5,959,000 -17,429,000 -36,001,000 16,380,000 3,443,000 -3,990,000 -8,011,000 2,731,000 -7,302,000 -8,453,000 42,784,000 -14,536,000 12,407,000 12,139,000 8,302,000 -13,749,000 -8,270,000 -15,101,000 10,112,000 -10,297,000 4,583,000 4,648,000 6,022,000 8,690,000 -2,889,000 2,593,000 -641,000 -1,638,000 2,925,000 3,658,000 1,964,000 6,074,000 25,719,000 -36,428,000 -1,872,000 -5,297,000 541,000 -2,118,000 228,000 -825,000 -443,000 
      other assets
    		-19,174,000 -11,881,000 -1,624,000 -41,861,000 -8,959,000 -10,750,000 -12,130,000 -10,337,000 -15,196,000 -5,293,000 -323,000 -31,999,000 2,991,000 7,709,000 1,440,000 -6,186,000 -728,000 -1,296,000 1,617,000 -23,104,000 56,000 -5,158,000 -441,000 -1,783,000 -2,519,000 -6,813,000 2,220,000 1,983,000 78,000 2,829,000 -670,000 -947,000 -1,639,000 -3,178,000 498,000 -1,775,000 -871,000 695,000 -307,000 -1,453,000 -221,000 2,329,000 -665,000 -1,478,000 -143,000 -2,746,000 -903,000 -572,000 -524,000 
      accounts payable and accrued liabilities
    		116,367,000 5,766,000 -2,655,000            -78,143,000 22,818,000 53,755,000 11,420,000 -72,304,000 -10,851,000 18,251,000 308,000 -94,733,000 55,342,000 59,318,000 4,499,000 -42,070,000 9,058,000 19,057,000 21,586,000 14,393,000 8,650,000 4,146,000      2,803,000 1,863,000 -4,046,000 6,486,000 -3,495,000 12,123,000 -7,681,000 11,197,000 1,990,000 5,278,000 -6,817,000 
      other long-term liabilities
    		16,355,000 3,468,000 2,069,000 4,532,000 3,520,000 3,400,000 3,309,000 9,252,000 7,229,000 2,842,000 4,262,000 10,185,000 -1,676,000 -3,286,000 1,710,000 -3,605,000 -316,000 -1,719,000 2,304,000 -16,096,000 3,287,000 794,000 5,144,000 742,000 -7,893,000 8,805,000 1,474,000 4,191,000 3,351,000 -2,591,000 4,390,000 943,000 450,000 860,000 693,000 -702,000 1,049,000             
      net cash from operating activities
    		368,685,000 185,271,000 174,394,000 185,627,000 221,481,000 118,762,000 46,971,000 27,483,000 135,646,000 70,062,000 -73,932,000 6,786,000 158,321,000 56,226,000 -45,431,000 11,180,000 97,060,000 82,784,000 113,512,000 -13,384,000 86,206,000 27,737,000 -15,194,000 57,343,000 70,125,000 -24,338,000 -54,868,000 -11,296,000 -9,492,000 11,986,000 14,214,000 -175,000 8,861,000 -15,782,000 9,057,000 22,221,000 3,250,000 19,466,000 29,075,000 19,171,000 20,020,000 3,967,000 1,885,000 7,193,000 -22,220,000 2,064,000 -9,733,000 -6,700,000 -20,126,000 
      capex
    		-28,447,000 -17,101,000 -16,768,000 -19,530,000 -18,463,000 -21,327,000 -26,104,000 -28,917,000 -21,735,000 -21,583,000 -24,456,000 -35,688,000 -29,300,000 -27,154,000 -28,817,000 -28,738,000 -18,734,000 -22,599,000 -25,507,000 -31,026,000 -16,570,000 -26,162,000 -40,554,000 -50,785,000 -32,854,000 -32,631,000 -28,756,000 -29,684,000 -13,202,000 -13,895,000 -15,013,000 -8,680,000 -56,388,000 0 -9,372,000 -15,240,000 -14,108,000 0 -26,559,000 -21,884,000 -18,737,000 -11,923,000 -12,113,000 0 -19,889,000 0 -5,648,000 0 -3,235,000 
      free cash flows
    		340,238,000 168,170,000 157,626,000 166,097,000 203,018,000 97,435,000 20,867,000 -1,434,000 113,911,000 48,479,000 -98,388,000 -28,902,000 129,021,000 29,072,000 -74,248,000 -17,558,000 78,326,000 60,185,000 88,005,000 -44,410,000 69,636,000 1,575,000 -55,748,000 6,558,000 37,271,000 -56,969,000 -83,624,000 -40,980,000 -22,694,000 -1,909,000 -799,000 -8,855,000 -47,527,000 -15,782,000 -315,000 6,981,000 -10,858,000 19,466,000 2,516,000 -2,713,000 1,283,000 -7,956,000 -10,228,000 7,193,000 -42,109,000 2,064,000 -15,381,000 -6,700,000 -23,361,000 
      cash flows from investing activities:
    		                                                 
      purchases of property, plant and equipment
    		-28,447,000 -17,101,000 -16,768,000 -19,530,000 -18,463,000 -21,327,000 -26,104,000 -28,917,000 -21,735,000 -21,583,000 -24,456,000 -35,688,000 -29,300,000 -27,154,000 -28,817,000 -28,738,000 -18,734,000 -22,599,000 -25,507,000 -31,026,000 -16,570,000 -26,162,000 -40,554,000 -50,785,000 -32,854,000 -32,631,000 -28,756,000 -29,684,000 -13,202,000 -13,895,000 -15,013,000 -8,680,000 -56,388,000                 
      maturities and sales of investments
    		98,809,000 117,934,000 77,804,000 154,582,000 160,787,000 186,116,000 131,533,000 113,186,000 260,614,000 275,945,000 215,118,000 142,751,000 165,646,000 155,780,000 155,818,000 188,937,000 153,171,000 154,304,000 194,637,000 210,610,000 175,113,000 75,410,000 94,701,000 104,533,000 212,201,000 203,583,000 219,894,000 56,018,000 77,526,000 72,378,000 58,412,000 54,897,000 81,455,000 70,622,000 85,057,000 28,627,000 22,055,000 102,250,000 46,359,000           
      purchases of investments
    		-110,829,000 -113,159,000 -89,274,000 -57,879,000 -156,909,000 -73,797,000 -121,665,000 -141,453,000 -282,994,000 -223,685,000 -220,364,000 -154,427,000 -152,577,000                                     
      proceeds from sale of nonfinancial assets
    		   0 0 0 10,000,000     -6,675,000 0 0 110,000,000     0 0 0 67,159,000                           
      purchase of intangible assets
    		-5,303,000   -769,000 -2,713,000 -512,000 -8,000,000 -7,779,000 -1,684,000 -1,147,000 -310,000 -671,000 -7,171,000 -881,000 -1,858,000 -15,621,000 -1,626,000 -3,653,000 -2,747,000 -8,838,000 -3,583,000 -7,323,000 -3,463,000 -10,057,000 -2,553,000                         
      acquisition, net of cash acquired
    		                                                 
      net cash from investing activities
    		-330,963,000 -12,592,000 -28,238,000 76,404,000 -16,157,000 90,480,000 -14,236,000 -64,963,000 -45,799,000 29,530,000 -30,012,000 -54,710,000 -23,402,000 -29,699,000 87,782,000 -55,421,000 -119,847,000 -120,257,000 -70,788,000 11,027,000 106,699,000 -248,751,000 77,404,000 -48,896,000 48,678,000 19,671,000 -50,479,000 -306,416,000 3,313,000 -52,353,000 -20,947,000 -34,914,000 -58,321,000 -13,610,000 -4,005,000 -13,129,000 -70,598,000 -45,521,000 -42,867,000 36,401,000 -27,688,000 -54,698,000 14,751,000 -80,492,000 101,362,000 -68,851,000 91,539,000 -203,288,000 29,604,000 
      cash flows from financing activities:
    		                                                 
      proceeds from exercises of awards under equity incentive plans
    		7,000   7,862,000 4,797,000 29,421,000 7,197,000 14,805,000 4,355,000 29,024,000 21,169,000 25,467,000 14,373,000 21,258,000 8,235,000 16,317,000 5,237,000 21,823,000 5,817,000 11,645,000 13,341,000 36,811,000 10,116,000 9,843,000 2,755,000 13,215,000 5,798,000                       
      taxes paid related to net share settlement of equity awards
    		-2,176,000 -12,310,000 -38,779,000 -4,909,000 -5,912,000 -16,791,000 -49,948,000 -3,920,000 -4,537,000 -16,440,000 -51,422,000 -3,587,000 -6,319,000 -11,428,000 -32,949,000 -1,377,000 -5,697,000 -9,634,000 -29,097,000 -1,971,000 -6,022,000 -7,801,000 -28,844,000 -1,729,000 -4,051,000 -6,795,000 -30,105,000                       
      repayments of convertible debt
    		   0                                              
      net cash from financing activities
    		-2,169,000 -4,603,000 -38,779,000 2,859,000 -499,125,000 12,612,000 -42,793,000 10,840,000 -788,000 11,963,000 -40,742,000 10,869,000 7,541,000 -11,780,000 -25,280,000 14,396,000 -1,031,000 10,951,000 -24,364,000 -366,155,000 3,256,000 563,688,000 -19,671,000 4,042,000 -1,975,000 -51,760,000 -24,981,000 704,928,000 12,299,000 39,564,000 10,306,000 10,107,000 7,758,000 -10,068,000 6,708,000 -2,276,000 9,140,000 1,448,000 5,521,000 -70,102,000 -653,000 2,414,000 2,372,000 5,518,000 12,505,000 3,306,000 4,908,000 316,666,000 -310,000 
      effect of exchange rate changes on cash
    		739,000 -3,063,000 -1,416,000 2,504,000 -2,901,000 3,300,000 1,927,000 -3,647,000 1,974,000 2,752,000 229,000 71,000 -747,000 -385,000 1,093,000 -22,000 -572,000 742,000 -205,000 1,995,000 614,000 -406,000 -3,353,000 1,737,000 -1,185,000 -365,000 715,000                       
      net increase in cash and cash equivalents
    		36,292,000 165,013,000 105,961,000 267,394,000 -296,702,000   -30,287,000 91,033,000 114,307,000 -144,457,000 -36,984,000 141,713,000 14,362,000 18,164,000 -29,867,000 -24,390,000 -25,780,000 18,155,000 -366,517,000 196,775,000 342,268,000 39,186,000 14,226,000    387,216,000 6,120,000 -803,000 3,573,000       -24,607,000 -8,272,000 -14,529,000 -8,321,000 -48,317,000 19,008,000 -67,781,000 91,647,000     
      cash and cash equivalents:
    		                                                 
      beginning of period
    		0 0 942,842,000 0 0 0 755,127,000 0 0 0 724,531,000 0 0 0 587,276,000 0 0 0 649,158,000 0 0 0 437,446,000 0 0 0 493,982,000 0 0 0 0 0 0  0 0 167,171,000  0 0 222,900,000  0 0 228,343,000  0 0 89,162,000 
      end of period
    		36,292,000 165,013,000 1,048,803,000 267,394,000 -296,702,000 225,154,000 746,996,000 -30,287,000 91,033,000 114,307,000 580,074,000 -36,984,000 141,713,000 14,362,000 605,440,000 -29,867,000 -24,390,000 -25,780,000 667,313,000 -366,517,000 196,775,000 342,268,000 476,632,000 14,226,000 115,643,000 -56,792,000 364,369,000 387,216,000 6,120,000 -803,000 3,573,000 -24,982,000 -41,702,000  11,760,000 6,816,000 108,963,000  -8,272,000 -14,529,000 214,579,000  19,008,000 -67,781,000 319,990,000  86,815,000 106,679,000 98,331,000 
      supplemental cash flow disclosures:
    		                                                 
      cash paid for interest
    		-65,000   3,707,000 1,528,000 3,706,000 1,420,000 3,663,000 1,465,000 3,738,000 1,437,000 3,706,000 1,438,000 3,715,000 1,422,000  1,478,000 3,730,000 1,465,000  1,461,000 2,751,000 1,403,000  1,482,000 2,812,000 1,483,000            2,155,000 3,045,000 2,153,000 3,045,000 2,146,000       
      cash paid for income taxes
    		7,823,000 51,997,000 10,388,000 21,181,000 13,204,000 20,583,000 2,301,000 21,625,000 23,504,000 23,819,000 4,364,000 40,947,000 1,604,000 10,505,000 1,316,000 2,622,000 5,372,000 7,161,000 2,998,000 4,622,000 1,395,000 693,000 2,267,000 3,638,000 2,155,000 3,027,000 906,000 1,732,000 1,777,000 991,000 677,000 1,009,000 1,088,000 677,000 1,721,000 929,000 254,000 1,758,000 253,000 406,000 407,000 1,029,000 145,000       
      supplemental cash flow disclosures for non-cash investing and financing activities:
    		                                                 
      increase in accounts payable and accrued liabilities related to fixed assets
    		2,293,000 6,479,000 -1,758,000 -15,187,000 -3,484,000 3,774,000 8,167,000 -7,813,000 -692,000                                         
      increase in accounts payable and accrued liabilities related to intangible assets
    		-3,878,000   8,442,000    455,000 8,793,000   966,000 -6,787,000 7,200,000 -637,000 39,000 7,992,000 99,000 1,298,000 2,751,000 -520,000                             
      impairment of assets
    		 0 2,967,000                                               
      decrease in accounts payable and accrued liabilities related to intangible assets
    		     16,802,000 -8,512,000    -1,478,000                                       
      amortization of premium (accretion of discount) on investments
    		       -2,447,000 -2,248,000 -2,563,000 -1,970,000          137,000                             
      impairment of assets and other non-cash adjustments
    		   0 5,685,000                                             
      non-cash changes in the fair value of contingent consideration
    		           -539,000 905,000 -651,000 1,989,000 1,772,000 1,766,000 2,233,000 2,255,000 3,148,000 1,936,000 -580,000 -4,000 -441,000 755,000 -7,369,000 12,260,000                       
      accounts payable and other short-term liabilities
    		   -100,259,000 122,280,000 4,745,000 -59,006,000 12,520,000 81,426,000 6,593,000 -31,686,000 61,416,000 73,947,000                                     
      payments of contingent consideration
    		       0 0 0 -9,475,000                                       
      principal repayments of financing leases
    		     -18,000 -42,000 -45,000 -606,000 -621,000 -1,014,000 -970,000 -513,000 -556,000 -566,000 -547,000 -551,000 -857,000 -1,084,000 -838,000 -4,033,000 -1,104,000 -943,000                           
      net decrease in cash and cash equivalents
    		      -8,131,000                   -56,792,000 -129,613,000     -24,982,000  -39,460,000 11,760,000 6,816,000 -58,208,000             
      loss on equity investment
    		        0 0 12,650,000                                       
      decrease in accounts payable and accrued liabilities related to fixed assets
    		          -8,430,000 3,758,000   -2,481,000  1,703,000 3,402,000 -12,795,000  9,978,000 -3,332,000 -19,927,000  -2,334,000 35,000 -3,502,000  14,616,000                     
      amortization of premium on investments
    		           -698,000 671,000 1,418,000 1,652,000 1,876,000 1,401,000 1,205,000 673,000                               
      inventory reserves, net of stock-based compensation
    		                                                 
      investment in convertible note
    		                   0 0                             
      repurchase of common stock
    		                   0 0                             
      proceeds from convertible senior subordinated note offering
    		                   0 -30,000                             
      payment of contingent consideration
    		            0                                     
      unrealized foreign exchange (gain) loss
    		              -6,887,000        9,400,000  -15,000 1,218,000 -419,000                       
      purchases of available-for-sale securities
    		              -147,361,000  -252,572,000 -247,401,000 -237,171,000  -48,258,000 -281,580,000 -40,104,000  -142,177,000 -146,477,000 -239,843,000                       
      stock-based compensation expense
    		                                                 
      purchase of available-for-sale debt securities
    		                                                 
      cash paid for interest, net of interest capitalized into fixed assets
    		                           -1,079,000 205,000 3,068,000 230,000 3,196,000 336,000 3,402,000 2,151,000 2,702,000 1,822,000             
      unrealized foreign exchange loss
    		                  3,950,000  6,881,000                             
      inventory write-off, net of stock-based compensation
    		                                                 
      payment of contingent acquisition consideration
    		                        -1,000                         
      (accretion of discount) amortization of premium on investments
    		                      60,000                           
      gain on sale of intangible assets
    		                       -10,000,000 0                         
      gain on sale of equity investment
    		                                                 
      proceeds from sale of intangible asset
    		                                                 
      conversion of convertible debt
    		                           16,269,000 31,512,000                     
      proceeds from sale of intangible assets
    		                                                 
      supplemental cash flow disclosures for non cash investing and financing activities:
    		                                                 
      (gain) loss on sale of equity investment
    		                                                 
      non-cash changes in the fair value of contingent consideration\
    		                                                 
      business acquisitions, net of cash acquired
    		                           0 0   0 0 0 -18,826,000 0 -14,124,000             
      proceeds from public offering of common stock
    		                           0 0 0 55,000                   
      gain on the sale of equity investments
    		                                                 
      non-cash changes in the fair value of contingent acquisition consideration
    		                                                 
      non-cash changes in the fair value of contingent acquisition consideration payable
    		                                                 
      payment of contingent acquisition consideration payable
    		                             -4,405,000  0 -1,894,000                 
      depreciation and amortization expense
    		                                                 
      gain on sale of intangible asset
    		                                                 
      deposit on purchase of pku rights
    		                                                 
      stock-based compensation capitalized into inventory
    		                           1,902,000 1,829,000 1,305,000 1,181,000 1,320,000 1,499,000 1,434,000 1,381,000 1,244,000 1,080,000 1,327,000 1,424,000 1,369,000 1,303,000 1,295,000 1,274,000       
      depreciation capitalized into inventory
    		                           2,795,000 2,830,000 2,591,000 2,469,000 2,509,000 2,065,000 2,480,000 2,045,000 1,543,000 1,466,000 1,173,000 1,920,000 689,000 650,000 714,000 741,000       
      (gain) loss on the sale of equity investments
    		                                                 
      impairment of intangible assets
    		                           0 0 0 0                   
      funds held in escrow for the purchase of real property
    		                                                 
      purchase of available-for-sale securities
    		                                                 
      proceeds from exercises of stock options and the espp
    		                                                 
      accrual for inventory purchases related to the acquisition of the merck pku business
    		                                                 
      unrealized foreign exchange gain on forward contracts
    		                               1,475,000        1,699,000 1,624,000 176,000 -304,000 61,000 -161,000     
      proceeds from exercises of stock options and the employee stock purchase plan
    		                                                 
      gain on termination of leases
    		                                                 
      purchase of available-for-sale investments
    		                           -215,850,000 -61,011,000 -105,351,000 -64,346,000 -131,000 -82,733,000                 
      investment in convertible promissory note
    		                                                 
      excess tax benefit from stock option exercises
    		                           -398,000 118,000 -377,000 -12,000 -306,000 -81,000 -509,000 -19,000   18,000 0 -127,000 -4,000         
      purchase of promissory note
    		                                                 
      proceeds from exercises of stock options and employee stock purchase plan
    		                                                 
      debt conversion expense
    		                           813,000 1,732,000 0  0                  
      proceeds from convertible senior note offering
    		                                                 
      purchase of capped call share options
    		                                                 
      payments for debt conversion
    		                           -813,000 -1,732,000                     
      supplemental cash flow disclosures from investing and financing activities:
    		                                                 
      gain on termination of lease
    		                                                 
      unrealized foreign exchange (gain) loss on forward contracts
    		                              -2,506,000   -551,000 -2,194,000 -1,415,000 -60,000 -3,725,000            
      release of escrow balance for purchase of san rafael corporate center
    		                                                 
      equity in the loss of biomarin/genzyme llc
    		                           438,000 147,000 253,000 336,000 609,000 608,000 796,000 640,000 864,000 691,000  1,320,000 -94,000 547,000         
      deferred offering costs reclassified into additional paid-in-capital as a result of conversion of convertible debt
    		                           147,000 303,000                     
      restricted funds held in escrow for the purchase of san rafael corporate center
    		                                                 
      investments in biomarin/genzyme llc
    		                           -400,000 0 -485,000 0 0 -655,000 -718,000 -1,450,000 0 -1,465,000 -740,000            
      proceeds from exercises of stock options and espp
    		                           12,094,000 14,293,000                     
      other non-cash movements
    		                                                 
      investment in biomarin/genzyme llc
    		                                                 
      proceeds from exercises of stock options
    		                                                 
      payment on maturity of 2013 convertible note
    		                           0 0                     
      repayment of capital lease obligations
    		                           -79,000 -144,000 -143,000 -142,000 -355,000 -53,000 -77,000 -33,000 -42,000 -43,000 -49,000 -45,000 -43,000 -48,000         
      loss on conversion of convertible promissory note
    		                                                 
      restricted funds held in escrow
    		                                                 
      purchase of intellectual property
    		                                                 
      increase in asset retirement obligation
    		                                                 
      unrealized foreign exchange loss on forward contracts
    		                            -295,000                     
      changes in the fair value of contingent acquisition consideration payable
    		                            8,832,000 12,113,000 617,000 595,000 2,234,000 -607,000 3,143,000 799,000 654,000             
      decrease in accrued liabilities related to fixed assets
    		                              318,000                   
      net gain from sale of investments
    		                               0 0 25,000 0 0 -927,000 0            
      payment on debt conversion
    		                                                 
      increase in accrued liabilities related to fixed assets
    		                                                 
      deferred offering costs reclassified into additional paid-in capital as a result of conversion of convertible debt
    		                                                 
      common stock transferred into the nonqualified deferred compensation plan
    		                                                 
      equipment acquired through capital leases
    		                               96,000 -176,000                 
      amortization of discount on investments
    		                              1,337,000 981,000 1,002,000                 
      proceeds from exercise of stock options and employee stock purchase plan
    		                              10,381,000                   
      net payment on debt conversion
    		                               0                  
      change in asset retirement obligation
    		                              49,000                   
      net provided by investing activities
    		                                                 
      imputed interest on acquisition obligation
    		                                 0 0   0 -282,000 1,782,000 1,077,000 1,083,000 1,089,000 1,098,000 1,108,000 1,117,000 1,128,000 1,136,000 1,146,000 
      impairment loss on equity investments
    		                                 0 0   0            
      proceeds from espp and exercise of stock options
    		                                    9,183,000   1,914,000 891,000 3,048,000 3,872,000 7,268,000 14,255,000 5,046,000 6,658,000 2,076,000 1,440,000 
      repayment of acquisition obligation
    		                                 0 0   0 0 -72,100,000 -1,500,000 -1,500,000 -1,500,000 -1,750,000 -1,750,000 -1,750,000 -1,750,000 -1,750,000 -1,750,000 
      asset retirement obligation
    		                                                 
      proceeds from employee stock purchase plan (espp) and exercise of stock options
    		                                11,858,000 13,215,000 6,722,000               
      cash flows from investing activities
    		                                                 
      changes in accrued liabilities related to fixed assets
    		                                 2,649,000 -13,396,000 1,313,000 4,477,000 -1,276,000 -19,000 -516,000 1,996,000 7,333,000 -3,725,000       
      changes in contingent acquisition consideration payable
    		                                  3,143,000 -19,657,000 21,110,000             
      amortization of discount (premium) on investments
    		                                 947,000 1,005,000 1,303,000 1,198,000 954,000            
      deferred revenue
    		                                 213,000 0 -158,000 72,000 -63,000 -780,000 809,000 -187,000 -1,136,000 -1,793,000 -1,643,000 -448,000 -1,586,000 -1,750,000 -1,788,000 -1,664,000 
      distributions from biomarin/genzyme llc
    		                                         0 4,000 0 16,679,000 0 6,200,000 4,900,000 6,000,000 
      investment in equity securities
    		                                 0 0               
      payment of contingent acquisition payable
    		                                 -9,631,000 0               
      beginning of year
    		                                                 
      end of year
    		                                                 
      distribution of inventory from the joint venture restructure
    		                                                 
      equipment acquired through capital lease obligations
    		                                                 
      accounts payable, accrued liabilities and other current liabilities
    		                                  2,565,000 8,322,000 -6,483,000             
      purchase of property, plant and equipment
    		                                  -9,372,000 -15,240,000 -14,108,000        -19,889,000  -5,648,000   
      purchase of investments
    		                                  -59,414,000 -26,516,000 -62,956,000 -106,893,000 -61,287,000           
      supplemental non-cash investing and financing activities disclosures:
    		                                                 
      investment in la jolla pharmaceutical company
    		                                     0 0 0 -6,250,000         
      equity in the (income) loss of biomarin/genzyme llc
    		                                          572,000 587,000 533,000     
      other liabilities
    		                                     -819,000 384,000 984,000 138,000 -326,000 995,000 148,000 143,000 -771,000 -425,000 798,000 401,000 
      investment in summit corporation plc
    		                                                 
      acquisition of huxley pharmaceuticals, inc.
    		                                                 
      payment to lead therapeutics, inc.
    		                                                 
      net proceeds from convertible debt offering
    		                                                 
      conversion of convertible notes
    		                                         157,000 6,000       
      distribution of inventory resulting from the joint venture restructure
    		                                         0 0       
      equipment acquired through capital lease
    		                                         90,000 143,000       
      deferred offering costs reclassified to additional paid in capital as a result of convertible notes
    		                                         5,000 0       
      common shares transferred to nonqualified deferred compensation plan
    		                                                 
      advances to biomarin/genzyme llc
    		                                      -91,000   32,000 42,000 75,000 1,764,000 -134,000 -651,000 -488,000 782,000 
      purchase of property and equipment
    		                                      -26,559,000 -21,884,000 -18,737,000 -11,923,000 -12,113,000      -3,235,000 
      proceeds from employee stock purchase plan and exercise of stock options
    		                                                 
      impairment loss on investments
    		                                       0 5,848,000         
      gain on sale of investments
    		                                                 
      amortization of discount on short-term investments
    		                                        -643,000 -1,018,000 -1,187,000 -1,443,000 -2,839,000 -3,445,000 -3,638,000 -3,177,000 -2,193,000 
      maturities and sales of short-term investments
    		                                        110,100,000 160,924,000 155,848,000 189,850,000 254,556,000     
      purchase of short-term investments
    		                                        -112,801,000 -201,731,000 -124,732,000 -257,643,000 -149,025,000 -251,445,000 -166,883,000 -317,178,000 -103,358,000 
      equity in the income of biomarin/genzyme llc
    		                                             -9,366,000 -8,446,000 -6,550,000 -6,163,000 
      impairment loss on investment
    		                                                 
      decrease in cash balances related to long-term debt
    		                                                 
      repayment of equipment and facility loans
    		                                                 
      net proceeds from public offering of common stock
    		                                                 
      cash flows from operating activities
    		                                                 
      investment summit corporation plc
    		                                                 
      settlement of forward contracts
    		                                          2,033,000 -256,000 -959,000     
      loss on disposals and impairment of property and equipment
    		                                                 
      loss on disposals and impairments of property and equipment
    		                                                 
      cash flows from financing activities
    		                                                 
      effect of foreign currency translation on cash
    		                                             -1,000 101,000 1,000 1,000 
      decrease in restricted cash
    		                                                 
      sale of short-term investments
    		                                             192,513,000 258,395,000 112,656,000 130,250,000 
      settlement of dispute with medicis
    		                                                 
      proceeds from equipment and facility loans
    		                                                 
      increase in cash balances related to long-term debt
    		                                                 
      loss on disposals of property and equipment
    		                                              0 0 9,000 
      net settlement of foreign currency forward contracts
    		                                              -525,000 -73,000 -53,000 
      proceeds from convertible debt offering
    		                                              0   
      net increase in cash
    		                                              86,815,000 106,679,000 9,169,000 
      stock based compensation
    		                                               4,691,000 3,815,000 
      equity in the loss (income) of biomarin/genzyme llc
    		                                                 
      acquired in-process research and development
    		                                                 
      impairment of acquired intangible assets
    		                                                 
      gain on disposals and impairments of property and equipment
    		                                                 
      notes receivable from officer
    		                                                 
      acquisition of ascent pediatrics
    		                                                 
      decrease (increase) in restricted cash
    		                                                 
      sales of short-term investments
    		                                                 
      purchases of short-term investments
    		                                                 
      reclassification of amounts (to) from cash balances related to long-term debt
    		                                                 
      proceeds from convertible debt offering, net of offering costs
    		                                                 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.